SEARCH

SEARCH BY CITATION

References

  • 1
    Goldman, J. M. and Melo, J. V., Chronic myeloid leukemia advances in biology and new approaches to treatment. N. Engl. J. Med. 2003. 349: 14511464.
  • 2
    O'Brien, S. G., Guilhot, F., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003. 348: 9941004.
  • 3
    Druker, B., Guilhot, F., O'brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. et al., Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N. Engl. J. Med. 2006. 355: 24082417.
  • 4
    Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E. and Davis, M. M., Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 2000. 6: 10181023.
  • 5
    Sacchi, S., Kantarjian, H., O’Brien, S. G., Cohen, P. R., Pierce, S. and Talpaz, M., Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J. Clin. Oncol. 1995. 13: 24012407.
  • 6
    Steegmann, J. L., Requena, M. J., Martín-Regueira, P., De La Cámara, R., Casado, F., Salvanés, F. R. and Fernández Rañada, J. M., High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha. Am. J. Hematol. 2003. 272: 170176.
  • 7
    Molldrem, J. J., Clave, E., Jiang, Y. Z., Mavroudis, D., Raptis, A., Hensel, N., Agarwala, V. et al., Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997. 90: 25292534.
  • 8
    Nieda, M., Nicol, A., Kikuchi, A., Kashiwase, K., Taylor, K., Suzuki, K., Tadokoro, K. et al., Dendritic cells stimulate the expansion of bcr-abl specific CD8+T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998. 91: 977983.
  • 9
    Bendelac, A., Savage, P. B. and Teyton, L., The biology of NKT cells. Ann. Rev. Immunol. 2007. 25: 297336.
  • 10
    Savage, A. K., Constantinides, M. G., Han, J., Picard, D., Martin, E., Li, B., Lantz, O. et al., The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008. 29: 391403.
  • 11
    Kovalovsky, D., Uche, O. U., Eladad, S., Hobbs, R. M., Yi, W., Alonzo, E., Chua, K. et al., The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol. 2008. 9: 10551064.
  • 12
    Smyth, M. J., Crowe, N. Y., Pellicci, D. G., Kyparissoudis, K., Kelly, J. M., Takeda, K., Yagita, H. et al., Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002. 99: 12591266.
  • 13
    Nakui, M., Ohta, A., Sekimoto, M., Sato, M., Wakabe, K., Yahata, T., Kitamura, H. et al., Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin. Exp. Metastasis 2000. 18: 147153.
  • 14
    Crowe, N. Y., Smyth, M. J. and Godfrey, D. I., A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 2002. 196: 119127.
  • 15
    Morris, E. S., MacDonald, K. P., Rowe, V., Banovic, T., Kuns, R. D., Don, A. L., Bofinger, H. M. et al., NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J. Clin. Invest. 2005. 115: 30933103.
  • 16
    Tahir, S. M., Cheng, O., Shaulov, A., Koezuka, Y., Bubley, G. J., Wilson, S. B., Balk, S. P. et al., Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 2001. 167: 40464050.
  • 17
    Yanagisawa, K., Seino, K., Ishikawa, Y., Nozue, M., Todoroki, T. and Fukao, K., Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha- galactosylceramide. J. Immunol. 2002. 168: 64946499.
  • 18
    Nowak, M., Arredouani, M. S., Tun-Kyi, A., Schmidt-Wolf, I., Sanda, M. G., Balk, S. P. and Exley, M. A., Defective NKT cell activation by CD1 d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galatosyl-ceramide. PLoS ONE 2010. 5: e11311.
  • 19
    Nieda, M., Nicol, A., Koezuka, Y., Kikuchi, A., Lapteva, N., Tanaka, Y., Tokunaga, K. et al., TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001. 97: 20672074.
  • 20
    Dhodapkar, M. V., Geller, M. D., Chang, D. H., Shimizu, K., Fujii, S., Dhodapkar, K. M. and Krasovsky, J., A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 2003. 197: 16671676.
  • 21
    Shimizu, K., Hidaka, M., Kadowaki, N., Makita, N., Konishi, N., Fujimoto, K., Uchiyama, T. et al., Evaluation of the function of human invariant NKT cells from cancer patients using alpha-Galactosyl-ceramide-loaded murine dendritic cells. J. Immunol. 2006. 177: 34843492.
  • 22
    Dong, R., Cwynarski, K., Entwistle, A., Marelli-Berg, F., Dazzi, F., Simpson, E., Goldman, J. M. et al., Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003. 101: 35603567.
  • 23
    Nieda, M., Okai, M., Tazbirkova, A., Lin, H., Yamaura, A., Ide, K., Abraham, R. et al., Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004. 103: 383389.
  • 24
    Rossignol, A., Barra, A., Herbelin, A., Preud'homme, J. L. and Gombert, J. M., Freshly isolated Valpha24(+) CD4(+) invariant natural killer T cells activated by alpha-galactosylceramide-pulsed B cells promote both IgG and IgE production. Clin. Exp. Immunol. 2007. 148: 555563.